A clinical outcomes and cost analysis comparing photoselective vaporization of the prostate to alternative minimally invasive therapies and transurethral prostate resection for the treatment of benign prostatic hyperplasia.

A clinical outcomes and cost analysis comparing photoselective vaporization of the prostate to alternative minimally invasive therapies and transurethral prostate resection for the treatment of benign prostatic hyperplasia.

PURPOSE: We critically evaluated the clinical outcomes and cost characteristics of alternative procedural treatment options for symptomatic benign prostatic hyperplasia. MATERIALS AND METHODS: An outcomes and cost analysis was performed for benign prostatic hyperplasia treatments, including photose...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Stovsky, MD, Griffiths, R, Duff, S
Format:	Journal article
Język:	English
Wydane:	2006

Podobne zapisy

Efficacy and safety of prostate artery embolisation for benign prostatic hyperplasia. An observational study and propensity matched comparison with transurethral resection of the prostate (the UK‐ROPE study)
od: Ray, A, i wsp.
Wydane: (2018)

Tuberculosis of the prostate presenting as benign prostatic hyperplasia.
od: Fazarina M,, i wsp.
Wydane: (2013)

Drug treatment for benign prostatic hyperplasia.
od: Farmer, A, i wsp.
Wydane: (1997)

Drug treatment for benign prostatic hyperplasia
od: Farmer, A, i wsp.
Wydane: (1997)

Cystic benign prostatic hyperplasia in a dog
od: Tan, W. X., i wsp.
Wydane: (2015)

Embolization in Haemorrhage-associated Transurethral Resection of Prostate: An Advancement of Endovascular Technique
od: Mohd Firdaus Mohd Hayati, i wsp.
Wydane: (2017)

Mortality trends for benign prostatic hyperplasia and prostate cancer in English populations 1979-2006.
od: Duncan, M, i wsp.
Wydane: (2011)

Development of robotic interstitial laser therapy for benign prostatic hyperplasia
od: Shee, Cheng Yap.
Wydane: (2008)

Transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia: Interventional procedures guidance [IPG625]
od: National Institute for Health and Care Excellence, CA, i wsp.
Wydane: (2018)

Transurethral water jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia: Interventional procedures guidance [IPG629]
od: National Institute for Health and Care Excellence, CA, i wsp.
Wydane: (2018)

A study on survivin expression in prostate cancer and benign prostatic hyperplasia; and its association with pre-operative serum prostate specific antigen and gleason score in prostate cancer
od: Hadi, Normila Abdul
Wydane: (2016)

A double-blind randomized controlled trial and economic evaluation of transurethral resection vs contact laser vaporization for benign prostatic enlargement: a 3-year follow-up.
od: Keoghane, SR, i wsp.
Wydane: (2000)

Effects of Bowman-Birk inhibitor concentrate (BBIC) in patients with benign prostatic hyperplasia.
od: Malkowicz, S, i wsp.
Wydane: (2001)

Maintaining a Healthy Balance: Targeting TERT to Stem Benign Prostatic Hyperplasia
od: Pickard, A, i wsp.
Wydane: (2015)

A double-blind randomized controlled trial and economic evaluation of transurethral resection vs contact laser vaporization for benign prostatic enlargement: a 3-year follow-up - Reply
od: Cranston, D
Wydane: (2000)

Shorter CAG repeats in androgen receptor and non-GG genotypes in prostate-specific antigen loci are associated with decreased risk of benign prostatic hyperplasia and prostate cancer.
od: Das, K, i wsp.
Wydane: (2008)

Prostate artery embolisation for lower urinary tract symptoms caused by benign prostatic hyperplasia: Interventional procedures guidance [IPG611]
od: National Institute for Health and Care Excellence, CA, i wsp.
Wydane: (2018)

Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials
od: Edwards, J, i wsp.
Wydane: (2002)

Identification of potential complementary serum biomarkers to differentiate prostate cancer from benign prostatic hyperplasia using gel- and lectin-based proteomics analyses
od: Jayapalan, J.J., i wsp.
Wydane: (2012)

Inhibitory effects of Pueraria mirifica aqueous extracts on 5α-reductase and prostate histomorphometry in testosterone induced benign prostatic hyperplasia Sprague Dawley rats
od: Masrudin, Siti Saleha, i wsp.
Wydane: (2023)

Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia: Interventional procedures guidance [IPG475]
od: National Institute for Health and Care Excellence, CA, i wsp.
Wydane: (2014)

A Study of Effectiveness of Alfuzosin in Benign Prostatic Hyperplasia Patients During Prostate Awareness Campaign in Year 2006-2009 in Hospital Universiti Sains Malaysia (HUSM)
od: Hood, Goh Cheng
Wydane: (2013)

Computer-assisted laser resection of the prostate (CALRP)
od: Ho, Gideon.
Wydane: (2008)

Attenuation of testosterone-induced benign prostatic hyperplasia with Andrographis paniculata (burm.f.) leaf extract in Wistar rats
od: Etti, Imaobong Christopher, i wsp.
Wydane: (2024)

Minimally invasive surgical modalities in the management of localized prostate cancer.
od: Jamal, K, i wsp.
Wydane: (2008)

FAKTOR PROGNOSTIK TERJADINYA KOMPLIKASI DINI PADA PASIEN PEMBESARAN PROSTAT JINAK PASCARESEKSI PROSTAT TRANSURETHRAL DI RSUP Dr. SARDJITO YOGYAKARTA
od: , RAKHMAD FAJARUDIN, i wsp.
Wydane: (2014)

Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.
od: Cao, Y, i wsp.
Wydane: (2002)

Prostate volume and its correlation with histopathological outcomes in prostate cancer.
od: Sooriakumaran, P, i wsp.
Wydane: (2011)

Follow-up of men with elevated prostate-specific antigen and one set of benign biopsies at prostate cancer screening.
od: Zackrisson, B, i wsp.
Wydane: (2003)

Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.
od: Steuber, T, i wsp.
Wydane: (2005)

Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen.
od: Steuber, T, i wsp.
Wydane: (2002)

Psychological well-being focusing on anxiety and depression among patients with lower urinary tract symptoms in benign prostatic hyperplasia on pharmacological treatment in HUSM
od: Tanapalla, Sejjeetra Raynee
Wydane: (2020)

Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study
od: Debruyne, F, i wsp.
Wydane: (2002)

Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study.
od: Debruyne, F, i wsp.
Wydane: (2002)

[Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study].
od: Debruyne, F, i wsp.
Wydane: (2002)

A highly conserved protein secreted by the prostate cancer cell line PC-3 is expressed in benign and malignant prostate tissue.
od: Valtonen-André, C, i wsp.
Wydane: (2007)

Expression of protein C inhibitor (PCI) in benign and malignant prostatic tissues.
od: Cao, Y, i wsp.
Wydane: (2003)

Total and gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies
od: Haese, A, i wsp.
Wydane: (2003)

Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
od: Haese, A, i wsp.
Wydane: (2003)

Peran urologi untuk mencapai visi Indonesia sehat 2010 bagi penduduk usia lanjut didalam manajemen pasien benign prostatic hyperplasia (BPH)
od: , Prawito Singodimedjo
Wydane: (2008)